InGeneron enrolled the first patients in a pivotal study evaluating autologous adipose-derived regenerative cells for the treatment of partial thickness rotator cuff tears involving the supraspinatus tendon.
The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of this point-of-care cell therapy. The trial will enroll 246 patients at up to 15 U.S. sites, including a group of patients who receive the cell therapy treatment and a control group that receives a corticosteroid injection, the current standard of care. Patients will be monitored for 48 weeks.
Additional clinical programs underway by InGeneron include feasibility studies for facet joint syndrome and wrist osteoarthritis.
InGeneron enrolled the first patients in a pivotal study evaluating autologous adipose-derived regenerative cells for the treatment of partial thickness rotator cuff tears involving the supraspinatus tendon.
The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of this point-of-care cell therapy. The...
InGeneron enrolled the first patients in a pivotal study evaluating autologous adipose-derived regenerative cells for the treatment of partial thickness rotator cuff tears involving the supraspinatus tendon.
The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of this point-of-care cell therapy. The trial will enroll 246 patients at up to 15 U.S. sites, including a group of patients who receive the cell therapy treatment and a control group that receives a corticosteroid injection, the current standard of care. Patients will be monitored for 48 weeks.
Additional clinical programs underway by InGeneron include feasibility studies for facet joint syndrome and wrist osteoarthritis.
Copy to clipboard 
